# US 2016/0355803 A1 · Methods of screening, selecting, and identifying cytotoxic recombinant polypeptides based on an interim diminution of ribotoxicity

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0355803 A1
- Document ID: US20160355803A1
- Status: Published application
- Kind: A1
- Application number: 15/117,174
- Filed: 2015-02-04
- Published: 2016-12-08
- Earliest claimed: 2014-02-05
- Assignees: Molecular Templates, Inc.
- Applicants: Molecular Templates, Inc.
- Inventors: Eric Poma; Erin Willert; Jason Kim; Jack Higgins
- Web page: https://patentgrep.com/patent/US20160355803A1

## CPC

- C12N 15/1062: {mRNA-Display, e.g. polypeptide and encoding template are connected covalently}
- C12N 15/1037: {Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display}
- C12N 15/1041: {Ribosome/Polysome display, e.g. SPERT, ARM}
- C40B 30/04: by measuring the ability to specifically bind a target molecule, e.g. antibody-antigen binding, receptor-ligand binding
- C07K 2319/00: Fusion polypeptide
- G01N 2500/20: cell-free systems
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C40B: COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES (in silico combinatorial libraries of nucleic acids, proteins or peptides G16B35/00; in silico combinatorial chemistry G16C20/60)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The present invention relates to methods of screening libraries of chimeric molecules comprising ribotoxic polypeptides, where screening is based on the interim reduction or elimination of ribotoxicity and the methods can identify cytotoxic molecules, each comprising a binding region and a ribotoxic region which jointly possess a desired assay-selectable characteristic, such as, e.g., binding to a target biomolecule, binding to a target cell, and/or cellular internalization.

## Claims

### Claim at position 1

1-53. (canceled)

### Claim 54

A method for identifying an amino acid sequence for use in constructing one or more chimeric cytotoxic protein,
wherein the one or more chimeric cytotoxic protein comprises:
i) a ribotoxic region comprising a polypeptide and capable of inactivating a ribosome, and
ii) a binding region comprising a polypeptide and capable of binding at least one target biomolecule;
wherein the method comprises the steps of:
a) providing a plurality of chimeric proteins, each protein comprising:
i) a modified ribotoxic region having at least one amino acid substitution, deletion, insertion, or addition as compared to a corresponding unmodified ribotoxin region, so as to reduce or eliminate ribotoxicity of the modified ribotoxic region thereby minimizing unwanted selection bias caused by the presence of ribotoxicity, and
ii) a binding region comprising a polypeptide and capable of binding at least one target biomolecule;
b) screening the plurality of chimeric proteins to identify a protein with at least one assay-screenable characteristic selected from:
target biomolecule binding affinity, target biomolecule binding selectivity, target cell binding affinity, target cell binding selectivity, target cell internalization, and improved expression; and
c) identifying the amino acid sequences of the polypeptide regions of the protein identified in step b) in order to construct one or more chimeric cytotoxic protein derived from the identified protein or comprising a binding region in the identified protein associated with a more ribotoxic form of a modified ribotoxic region present in the identified protein.

### Claim 55 (depends on 54)

The method of claim 54, further comprising the step of:
d) producing the one or more chimeric cytotoxic protein, wherein the producing step comprises:
i) providing a polynucleotide encoding the one or more chimeric cytotoxic protein, and
ii) expressing the polynucleotide using a host cell or cell-free translation system.

### Claim 56 (depends on 54)

The method of claim 54, wherein the one or more chimeric cytotoxic protein is a fusion polypeptide comprising the ribotoxin region fused to the binding region.

### Claim 57 (depends on 56)

The method of claim 56, wherein the plurality of chimeric proteins is a plurality of fusion polypeptides, each fusion polypeptide comprising the modified ribotoxin region fused to a binding region comprising a polypeptide and capable of binding at least one target biomolecule.

### Claim 58 (depends on 57)

The method of claim 57, wherein the modified ribotoxic region is derived from a toxin selected from the group consisting of:
abrin, agrostin, amarandin, amaranthin, Amaranthus antiviral/RIP, angiogenin, A. patens RIP, Articulatin D, asparin, aspergillin, Aspfl, balsamin, B. hispida RIP, bouganin, Bougainvillea×buttiana antiviral protein 1, benincasin, bouganin, B. rubra RIP, bryodin, B. spectabilis RIP, B. vulgaris RIP, C. album RIP, camphorin, C. aculeatum-systemic resistance inducing protein, C. cristata RIP, C. figarei RIP, charantin, charybdin, cinnamomin, clavin, C. moschata RIP, cochinin B, colocins, crotin, cucurmosin, curcin, Dianthus spp. RIP, Corynebacterium spp. diphtheria toxin, dodecandrin, ebulin, ebulitin, E. hyemalis RIP, euserratin, eutirucallin, flammin, flammulin, foetidissimin, gelonin, gigantin, gypsophilin, H. crepitans RIP, Heterotepalin, hispin, hirsutellin A, H. orientalis RIP, H. vulgare RIP, hypsin, insularin, I. hollandica RIP, lagenin, lamjapin, lanceolin, L. cylindrical RIP, luffacylin, luffaculin, luffagulin, luffin, L. usitatissimum RIP, lychnin, lyophyllin, manutin, marmorin, mapalmin, M. charantia lectin, M. crystallinum RIP, melonin, mexin, Mirabilis spp. RIP, mitogillin, modeccin, MOR, Mormordica spp. RIP, momorsgrovin, moschatin, musarmin, N. tabacum RIP, nigrin, nigritin, ocymoidin, pachyerosin, P. californicum lectin, pepocin, petroglaucin, petrograndin, Phytolacca spp. RIP, pisavin, pleuturegin, Pluturegin, A. thaliana pectin methyl transferase, P. multiforum RIP, pokeweed antiviral protein, porrectin, Aeromonas spp. Pseudomonas toxin (A. hydrophila pseudomonas-like toxin), pulchellin, quinqueginsin, R. communis agglutinin, restrictocin, ricin, riproximin, saporin, sarcin, sativin, S. cereale RIP, sechiumin, Shiga toxin, Shiga-like toxin, sieboldin b, S. nigra RIP, S. ocymoides RIP, Spinacia oleracea protein, stellarin, stenodactylin, texanin, tricholin, Trichosanthes spp. RIP, Triticum spp. RIP, V. album RIP, velin, velutin, verotoxin, V. hispanica RIP, vircumin, volkensin, V. volvacea RIP, Volvarin, Yucca leaf protein, Z. diploperennis RIP, Z. mays RIP, and any ribotoxic fragment of any of the foregoing.

### Claim 59 (depends on 58)

The method of claim 58, further comprising before step a), the steps of:
a′) providing an expression library of diverse nucleic acids constructed from a plurality of polynucleotides encoding a plurality of fusion polypeptides; and
b′) expressing the expression library of diverse nucleic acids such that a plurality of fusion polypeptides is produced.

### Claim 60 (depends on 59)

The method of claim 59, further comprising before step a′), the steps of:
a″) providing a library comprising a plurality of diverse polynucleotides encoding a plurality of binding regions, wherein at least two subsets of polynucleotides encode polypeptides with different binding regions; and
b″) joining the polynucleotides of the library to a toxin template polynucleotide encoding a modified ribotoxic region in an operable combination to construct an expression library of diverse nucleic acids that encode a plurality of fusion polypeptides, each fusion polypeptide comprising a binding region fused with the modified ribotoxic region; and
optionally,
c″) recombining the polynucleotides of the library of joined polynucleotides to an expression polynucleotide template to construct an expression library of diverse nucleic acids capable of expressing a plurality of fusion polypeptides, each fusion polypeptide comprising a binding region fused to the modified ribotoxic region.

### Claim 61 (depends on 59)

The method of claim 59, wherein the binding region is selected from the group consisting of:
complementary determining region 3 fragment, constrained FR3-CDR3-FR4 polypeptide, single-domain antibody fragment, single-chain variable fragment, antibody variable fragment, antigen-binding fragment, Fd fragment, fibronectin-derived 10th fibronectin type III domain, tenascin type III domain, ankyrin repeat motif domain, low-density-lipoprotein-receptor-derived A-domain, lipocalin, Kunitz domain, Protein-A-derived Z domain, gamma-B crystalline-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide, Fyn-derived SH2 domain, engineered antibody mimic, and any genetically manipulated counterparts of any of the foregoing that retain binding functionality.

### Claim 62 (depends on 61)

The method of claim 61, wherein the expression library is operable using a protein display method selected from the group consisting of:
bacteriophage display, RNA display, ribosome display, DNA display, bead surface display, virus display, microorganism display, and mammalian cell display.

### Claim 63 (depends on 62)

The method of claim 62, wherein at least one binding region is capable of binding to a target biomolecule found in physical association with at least one type of malignant cell.

### Claim 64 (depends on 63)

The method of claim 63, wherein the modified ribotoxic region comprises or consists of an amino acid sequence that has at least 90%, 95%, 97%, 98%, 99%, 99.5%, or 99.7% sequence identity to a sequence selected from any one of SEQ ID NOs: 1-39 or a ribotoxic fragment thereof.

### Claim 65 (depends on 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64)

A method for producing a nucleic acid encoding a chimeric cytotoxic protein, wherein the chimeric cytotoxic protein comprises a ribotoxin region, which is capable of inactivating a ribosome, fused to a binding region capable of binding at least one target biomolecule; the method comprising the steps of:
a) identifying the amino acid sequence of a binding region of a chimeric protein using the method of any one of claims 54-64, and
b) creating a nucleic acid encoding the chimeric cytotoxic protein, wherein the binding region consists essentially of, comprises, or is derived from a binding region of the chimeric protein identified in step a), and the ribotoxic region is more ribotoxic than the modified ribotoxic region of the chimeric protein identified in step a).

### Claim 66

A method for identifying an amino acid sequence for use in constructing one or more chimeric cytotoxic protein,
wherein the one or more chimeric cytotoxic protein comprises:
i) a ribotoxic region comprising a polypeptide and capable of inactivating a ribosome, and
ii) a binding region comprising a polypeptide and capable of binding at least one target biomolecule, and,
wherein the method comprises the steps of:
a) providing a plurality of chimeric cytotoxic proteins, each protein comprising:
i) a ribotoxic region comprising a polypeptide and capable of inactivating a ribosome, and
ii) a binding region comprising a polypeptide and capable of binding at least one target biomolecule;
b) screening the plurality of chimeric cytotoxic proteins in the presence of an inhibitor of the ribotoxic region to identify a protein with at least one assay-screenable characteristic, wherein the at least one characteristic is selected from: target biomolecule binding affinity, target biomolecule binding selectivity, target cell binding affinity, target cell binding selectivity, target cell internalization, and improved expression; and
c) identifying the amino acid sequence(s) of the chimeric cytotoxic protein identified in step b).

### Claim 67 (depends on 66)

The method of claim 66, wherein the one or more chimeric cytotoxic protein is a fusion polypeptide comprising the ribotoxin region fused to the binding region.

### Claim 68 (depends on 67)

The method of claim 67, wherein the plurality of chimeric cytotoxic proteins is a plurality of fusion polypeptides, each fusion polypeptide comprising the ribotoxin region fused to the binding region.

### Claim 69 (depends on 68)

The method of claim 68, wherein the expression library is operable using a protein display method selected from the group consisting of:
bacteriophage display, RNA display, ribosome display, DNA display, bead surface display, virus display, microorganism display, and mammalian cell display.

### Claim 70 (depends on 68)

The method of claim 68, further comprising the step of:
d) producing the one or more chimeric cytotoxic protein consisting essentially of, comprising, or derived from the identified amino acid sequence of the chimeric cytotoxic protein; wherein the producing step comprises:
i) providing a polynucleotide encoding the one or more chimeric cytotoxic protein and
ii) expressing the polynucleotide using a host cell or cell-free translation system.

### Claim 71 (depends on 68)

The method of claim 68, further comprising before step a), the steps of:
a′) providing an expression library of diverse nucleic acids constructed from a plurality of polynucleotides encoding a plurality of fusion polypeptides, each fusion polypeptide comprising:
i) a ribotoxic region capable of inactivating a ribosome and
ii) a binding region capable of binding at least one target biomolecule;
b′) expressing the expression library of diverse nucleic acids such that a plurality of fusion polypeptides is produced.

### Claim 72 (depends on 71)

The method of claim 71, further comprising before step a′), the steps of:
a″) providing a library comprising a plurality of diverse polynucleotides encoding a plurality of binding regions, wherein at least two subsets of polynucleotides encode polypeptides with different binding regions; and
b″) joining the polynucleotides of the library to a toxin template polynucleotide encoding a ribotoxic region in an operable combination to construct an expression library of diverse nucleic acids that encode a plurality of fusion polypeptides, each fusion polypeptide comprising the ribotoxic region and one of the binding regions; and
optionally
c″) recombining the polynucleotides of the library of polynucleotides to an expression polynucleotide template to construct an expression library of diverse nucleic acids capable of expressing a plurality of fusion polypeptides, each fusion polypeptide comprising the ribotoxic region and one of the binding regions.

### Claim 73 (depends on 68)

The method of claim 68, wherein the ribotoxic region is derived from a toxin selected from the group consisting of:
abrin, agrostin, amarandin, amaranthin, Amaranthus antiviral/RIP, angiogenin, A. patens RIP, Articulatin D, asparin, aspergillin, Aspfl, balsamin, B. hispida RIP, bouganin, Bougainvillea×buttiana antiviral protein 1, benincasin, bouganin, B. rubra RIP, bryodin, B. spectabilis RIP, B. vulgaris RIP, C. album RIP, camphorin, C. aculeatum-systemic resistance inducing protein, C. cristata RIP, C. figarei RIP, charantin, charybdin, cinnamomin, clavin, C. moschata RIP, cochinin B, colocins, crotin, cucurmosin, curcin, Dianthus spp. RIP, Corynebacterium spp. diphtheria toxin, dodecandrin, ebulin, ebulitin, E. hyemalis RIP, euserratin, eutirucallin, flammin, flammulin, foetidissimin, gelonin, gigantin, gypsophilin, H. crepitans RIP, Heterotepalin, hispin, hirsutellin A, H. orientalis RIP, H. vulgare RIP, hypsin, insularin, I. hollandica RIP, lagenin, lamjapin, lanceolin, L. cylindrical RIP, luffacylin, luffaculin, luffagulin, luffin, L. usitatissimum RIP, lychnin, lyophyllin, manutin, marmorin, mapalmin, M. charantia lectin, M. crystallinum RIP, melonin, mexin, Mirabilis spp. RIP, mitogillin, modeccin, MOR, Mormordica spp. RIP, momorsgrovin, moschatin, musarmin, N. tabacum RIP, nigrin, nigritin, ocymoidin, pachyerosin, P. californicum lectin, pepocin, petroglaucin, petrograndin, Phytolacca spp. RIP, pisavin, pleuturegin, Pluturegin, A. thaliana pectin methyl transferase, P. multiforum RIP, pokeweed antiviral protein, porrectin, Aeromonas spp. Pseudomonas toxin (A. hydrophila pseudomonas-like toxin), pulchellin, quinqueginsin, R. communis agglutinin, restrictocin, ricin, riproximin, saporin, sarcin, sativin, S. cereale RIP, sechiumin, Shiga toxin, Shiga-like toxin, sieboldin b, S. nigra RIP, S. ocymoides RIP, Spinacia oleracea protein, stellarin, stenodactylin, texanin, tricholin, Trichosanthes spp. RIP, Triticum spp. RIP, V. album RIP, velin, velutin, verotoxin, V. hispanica RIP, vircumin, volkensin, V. volvacea RIP, Volvarin, Yucca leaf protein, Z. diploperennis RIP, Z. mays RIP, and any ribotoxic fragment of any of the foregoing.

### Claim 74 (depends on 68)

The method of claim 68, wherein the binding region is selected from the group consisting of:
complementary determining region 3 fragment, constrained FR3-CDR3-FR4 polypeptide, single-domain antibody fragment, single-chain variable fragment, antibody variable fragment, antigen-binding fragment, Fd fragment, fibronectin-derived 10th fibronectin type III domain, tenascin type III domain, ankyrin repeat motif domain, low-density-lipoprotein-receptor-derived A-domain, lipocalin, Kunitz domain, Protein-A-derived Z domain, gamma-B crystalline-derived domain, ubiquitin-derived domain, Sac7d-derived polypeptide, Fyn-derived SH2 domain, engineered antibody mimic, and any genetically manipulated counterparts of any of the foregoing that retain binding functionality.

### Claim 75 (depends on 74)

The method of claim 74, wherein at least one binding region is capable of binding to a target biomolecule found in physical association with at least one type of malignant cell.

### Claim 76 (depends on 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

A method for producing a nucleic acid encoding a chimeric cytotoxic protein, the method comprising the steps of:
a) identifying the amino acid sequence of a chimeric cytotoxic protein using the method of any one of claims 66-75 and
b) creating a nucleic acid encoding a chimeric cytotoxic protein consisting essentially of, comprising, or derived from the identified amino acid sequence, wherein the encoded chimeric cytotoxic protein comprises a binding region capable of binding at least one target biomolecule fused to a ribotoxic region capable of inactivating a ribosome.
